Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 24, 2023 09:00 ET | Source: Tarsus Pharmaceuticals, Inc

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available...
December 15, 2022 08:30 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease

Positive Phase 1b Callisto data shows that TP-05 is well tolerated and safety data supports progression to Phase 2a Phase 2a Carpo trial to evaluate the safety, tolerability, and proof-of-activity of...
October 25, 2022 08:30 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting

Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus recently submitted NDA to the FDA for TP-03 Data from an investigator-initiated trial evaluating...
January 19, 2021 08:30 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel

IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...
January 07, 2021 09:24 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Pharmaceuticals, Inc. Appoints Dianne Whitfield as Chief Human Resources Officer

IRVINE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...
December 21, 2020 07:00 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Pharmaceuticals, Inc. Announces Inclusion in the Russell 3000® Index and Russell 2000® Index

IRVINE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...
October 20, 2020 16:05 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise by the Underwriters of Option to Purchase Additional Shares

IRVINE, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus”), a late clinical-stage biopharmaceutical company focused on the development and commercialization of...
October 15, 2020 20:35 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Pharmaceuticals Inc. Announces Pricing of Initial Public Offering

IRVINE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc., (“Tarsus”) a late clinical-stage biopharmaceutical company focused on the development and commercialization of...